Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ALNY stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tazeen Ahmad has given his Buy rating due to a combination of factors that highlight Alnylam Pharma’s promising future prospects. One of the key reasons is the strong commercial potential of the ATTR-CM franchise, particularly with the launch of Amvuttra, which is expected to provide a significant revenue stream and support the expansion of the siRNA platform into additional indications. The company’s next-generation asset, nucresiran, is also seen as a major long-term value driver due to its convenient dosing schedule, extended intellectual property protection, and lack of royalty obligations compared to Amvuttra.
Moreover, the initiation of phase 3 trials for nucresiran in both ATTR-CM and ATTR-PN further strengthens the company’s pipeline, with expectations of significant market launches in the coming years. While there are some concerns regarding zilebesiran’s performance in hypertension, the overall outlook remains positive, with the potential for differentiation if future trials yield favorable results. These factors, combined with a revised price objective of $520, underpin Ahmad’s confidence in Alnylam Pharma’s growth trajectory and justify the Buy rating.
In another report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $566.00 price target.